Annual EBITDA
-$105.20 M
+$55.85 M+34.68%
December 31, 2023
Summary
- As of February 25, 2025, TSHA annual EBITDA is -$105.20 million, with the most recent change of +$55.85 million (+34.68%) on December 31, 2023.
- During the last 3 years, TSHA annual EBITDA has fallen by -$45.22 million (-75.40%).
- TSHA annual EBITDA is now -75.40% below its all-time high of -$59.97 million, reached on December 31, 2020.
Performance
TSHA EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$25.21 M
-$4.63 M-22.48%
September 30, 2024
Summary
- As of February 25, 2025, TSHA quarterly EBITDA is -$25.21 million, with the most recent change of -$4.63 million (-22.48%) on September 30, 2024.
- Over the past year, TSHA quarterly EBITDA has stayed the same.
- TSHA quarterly EBITDA is now -151.63% below its all-time high of $48.82 million, reached on December 31, 2023.
Performance
TSHA Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$20.67 M
+$90.08 M+81.33%
September 30, 2024
Summary
- As of February 25, 2025, TSHA TTM EBITDA is -$20.67 million, with the most recent change of +$90.08 million (+81.33%) on September 30, 2024.
- Over the past year, TSHA TTM EBITDA has stayed the same.
- TSHA TTM EBITDA is now -1753.99% below its all-time high of -$1.11 million, reached on December 1, 2019.
Performance
TSHA TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
TSHA EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +34.7% | 0.0% | 0.0% |
| 3 y3 years | -75.4% | 0.0% | 0.0% |
| 5 y5 years | - | 0.0% | 0.0% |
TSHA EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +39.0% | -151.6% | +78.1% | at high | +90.0% |
| 5 y | 5-year | -75.4% | +39.0% | -151.6% | +78.1% | -1754.0% | +90.0% |
| alltime | all time | -75.4% | +39.0% | -151.6% | +78.1% | -1754.0% | +90.0% |
Taysha Gene Therapies EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$25.21 M(+22.5%) | -$20.67 M(-81.3%) |
| Jun 2024 | - | -$20.58 M(-13.2%) | -$110.75 M(-2.0%) |
| Mar 2024 | - | -$23.71 M(-148.6%) | -$112.99 M(+7.4%) |
| Dec 2023 | -$105.20 M(-34.7%) | $48.82 M(-142.3%) | -$105.20 M(-49.3%) |
| Sep 2023 | - | -$115.28 M(+405.3%) | -$207.43 M(+76.8%) |
| Jun 2023 | - | -$22.82 M(+43.3%) | -$117.31 M(-8.0%) |
| Mar 2023 | - | -$15.92 M(-70.2%) | -$127.58 M(-20.8%) |
| Dec 2022 | -$161.04 M | -$53.41 M(+112.2%) | -$161.04 M(+2.5%) |
| Sep 2022 | - | -$25.17 M(-23.9%) | -$157.12 M(-13.9%) |
| Jun 2022 | - | -$33.08 M(-33.0%) | -$182.43 M(-4.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | -$49.38 M(-0.2%) | -$190.00 M(+10.1%) |
| Dec 2021 | -$172.60 M(+187.8%) | -$49.49 M(-2.0%) | -$172.60 M(+22.0%) |
| Sep 2021 | - | -$50.48 M(+24.2%) | -$141.43 M(+33.4%) |
| Jun 2021 | - | -$40.65 M(+27.1%) | -$105.99 M(+22.4%) |
| Mar 2021 | - | -$31.99 M(+74.7%) | -$86.56 M(+44.3%) |
| Dec 2020 | -$59.97 M | - | - |
| Dec 2020 | - | -$18.31 M(+21.8%) | -$59.97 M(+40.2%) |
| Sep 2020 | - | -$15.04 M(-29.1%) | -$42.78 M(+54.2%) |
| Jun 2020 | - | -$21.22 M(+292.7%) | -$27.74 M(+325.5%) |
| Mar 2020 | - | -$5.40 M(+384.7%) | -$6.52 M(+484.7%) |
| Dec 2019 | - | -$1.11 M | -$1.11 M |
FAQ
- What is Taysha Gene Therapies annual EBITDA?
- What is the all time high annual EBITDA for Taysha Gene Therapies?
- What is Taysha Gene Therapies annual EBITDA year-on-year change?
- What is Taysha Gene Therapies quarterly EBITDA?
- What is the all time high quarterly EBITDA for Taysha Gene Therapies?
- What is Taysha Gene Therapies quarterly EBITDA year-on-year change?
- What is Taysha Gene Therapies TTM EBITDA?
- What is the all time high TTM EBITDA for Taysha Gene Therapies?
- What is Taysha Gene Therapies TTM EBITDA year-on-year change?
What is Taysha Gene Therapies annual EBITDA?
The current annual EBITDA of TSHA is -$105.20 M
What is the all time high annual EBITDA for Taysha Gene Therapies?
Taysha Gene Therapies all-time high annual EBITDA is -$59.97 M
What is Taysha Gene Therapies annual EBITDA year-on-year change?
Over the past year, TSHA annual EBITDA has changed by +$55.85 M (+34.68%)
What is Taysha Gene Therapies quarterly EBITDA?
The current quarterly EBITDA of TSHA is -$25.21 M
What is the all time high quarterly EBITDA for Taysha Gene Therapies?
Taysha Gene Therapies all-time high quarterly EBITDA is $48.82 M
What is Taysha Gene Therapies quarterly EBITDA year-on-year change?
Over the past year, TSHA quarterly EBITDA has changed by $0.00 (0.00%)
What is Taysha Gene Therapies TTM EBITDA?
The current TTM EBITDA of TSHA is -$20.67 M
What is the all time high TTM EBITDA for Taysha Gene Therapies?
Taysha Gene Therapies all-time high TTM EBITDA is -$1.11 M
What is Taysha Gene Therapies TTM EBITDA year-on-year change?
Over the past year, TSHA TTM EBITDA has changed by $0.00 (0.00%)